Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

Mol Cancer Ther (2019) 18 (11): 2182.

https://doi.org/10.1158/1535-7163.MCT-19-0749

Published: 01 November 2019

View article titled, Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

Journal Articles

Neutralization of BCL-2/X_L Enhances the Cytotoxicity of T-DM1 In Vivo

Jason J. Zoeller, Aleksandr Vagodny, Krishan Taneja, Benjamin Y. Tan, Neil O'Brien, Dennis J. Slamon, Deepak Sampath, Joel D. Leverson, Roderick T. Bronson, Deborah A. Dillon, Joan S. Brugge

Mol Cancer Ther (2019) 18 (6): 1115–1126.

https://doi.org/10.1158/1535-7163.MCT-18-0743

Published: 03 June 2019

View article titled, Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo

Includes: Supplementary data

Journal Articles

Combined MEK and BCL-2/X_L Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Claudia Iavarone, Ioannis K. Zervantonakis, Laura M. Selfors, Sangeetha Palakurthi, Joyce F. Liu, Ronny Drapkin, Ursula A. Matulonis, Dorothy Hallberg, Victor E. Velculescu, Joel D. Leverson, Deepak Sampath, Gordon B. Mills, Joan S. Brugge

Mol Cancer Ther (2019) 18 (3): 642–655.

https://doi.org/10.1158/1535-7163.MCT-18-0413

Published: 01 March 2019

View article titled, Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

Includes: Supplementary data

Journal Articles

An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

Mol Cancer Ther (2018) 17 (3): 638–649.

https://doi.org/10.1158/1535-7163.MCT-17-0813

Published: 28 February 2018

View article titled, An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract B052: FLT3-ITD activation mediates resistance to the BCL-2 selective antagonist, venetoclax, in FLT3-ITD mutant AML models

Raghuveer Mali, Elisabeth A. Lasater, Kelly Doyle, Ritu Malla, Erwin Boghaert, Andrew Souers, Joel Leverson, Deepak Sampath

Mol Cancer Ther (2018) 17 (1_Supplement): B052.

https://doi.org/10.1158/1535-7163.TARG-17-B052

Published: 01 January 2018

View article titled, Abstract B052: FLT3-ITD activation mediates resistance to the BCL-2 selective antagonist, venetoclax, in FLT3-ITD mutant AML models

Journal Articles

Expression Profile of BCL-2, BCL-X_L, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Mol Cancer Ther (2016) 15 (5): 1132–1144.

https://doi.org/10.1158/1535-7163.MCT-15-0730

Published: 05 May 2016

View article titled, Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Includes: Supplementary data

Journal Articles

Abstract B190: GDC-0068 is a novel and selective Akt inhibitor that enhances the efficacy of FOLFOX in primary gastric cancer models.

Ellen Ingalla, Rebecca Hong, Heidi Savage, Elizabeth Punnoose, Sandra Rost, Hartmut Koeppen, Deepak Sampath, Michelle A. Nannini

Mol Cancer Ther (2013) 12 (11_Supplement): B190.

https://doi.org/10.1158/1535-7163.TARG-13-B190

Published: 01 November 2013

View article titled, Abstract B190: GDC-0068 is a novel and selective Akt inhibitor that enhances the efficacy of FOLFOX in primary gastric cancer models.

Journal Articles

Abstract B154: Co-administration of nicotinic acid with NAMPT small molecule inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

Deepak Sampath, Jason Oeh, Yang Xiao, Xiaorong Liang, Alexander Vanderbilt, Ann Qin, LuLu Yang, Leslie Lee, Justin Ly, Ely Cosino, Jennifer LaCap, Annie Ogasawara, Simon Williams, Michelle Nannini, Bianca Liederer, Peter Jackson, Peter Dragovich, Thomas O'Brien

Mol Cancer Ther (2013) 12 (11_Supplement): B154.

https://doi.org/10.1158/1535-7163.TARG-13-B154

Published: 01 November 2013

View article titled, Abstract B154: Co-administration of nicotinic acid with NAMPT small molecule inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

Journal Articles

Abstract A245: Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.

Deepak Sampath, Sylvia Herter, Ellen Ingalla, Frank Herting, Marina Bacac, Michelle Nannini, Wayne J. Fairbrother, Christian Klein

Mol Cancer Ther (2013) 12 (11_Supplement): A245.

https://doi.org/10.1158/1535-7163.TARG-13-A245

Published: 01 November 2013

View article titled, Abstract A245: Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.

Journal Articles

Abstract C150: Depletion of cellular NAD using the NAMPT inhibitor GNE-617 leads to oncosis blister cell death.

Thomas O'Brien, Christopher Del Nagro, Yang Xiao, Jason Oeh, Linda Rangell, Mike Reichelt, Xiaorong Liang, Bianca M. Liederer, Peter S. Dragovich, Deepak Sampath

Mol Cancer Ther (2013) 12 (11_Supplement): C150.

https://doi.org/10.1158/1535-7163.TARG-13-C150

Published: 01 November 2013

View article titled, Abstract C150: Depletion of cellular NAD using the NAMPT inhibitor GNE-617 leads to oncosis blister cell death.

Journal Articles

Bcl-2/Bcl-x_L Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Nguyen Tan, Maureen Wong, Michelle A. Nannini, Rebecca Hong, Leslie B. Lee, Stephen Price, Karen Williams, Pierre Pascal Savy, Peng Yue, Deepak Sampath, Jeffrey Settleman, Wayne J. Fairbrother, Lisa D. Belmont

Mol Cancer Ther (2013) 12 (6): 853–864.

https://doi.org/10.1158/1535-7163.MCT-12-0949

Published: 09 June 2013

View article titled, Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Includes: Supplementary data

Journal Articles

The Bcl-2/Bcl-X_L/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

Mol Cancer Ther (2011) 10 (12): 2340–2349.

https://doi.org/10.1158/1535-7163.MCT-11-0415

Published: 07 December 2011

View article titled, The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

Includes: Supplementary data

Journal Articles

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Mol Cancer Ther (2011) 10 (12): 2426–2436.

https://doi.org/10.1158/1535-7163.MCT-11-0446

Published: 07 December 2011

View article titled, GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Includes: Supplementary data

Journal Articles

Abstract C201: A novel potent and selective inhibitor of PI3K/mTOR, GDC‐0980, currently in phase I clinical trials

Mol Cancer Ther (2009) 8 (12_Supplement): C201.

https://doi.org/10.1158/1535-7163.TARG-09-C201

Published: 10 December 2009

View article titled, Abstract C201: A novel potent and selective inhibitor of PI3K/mTOR, GDC‐0980, currently in phase I clinical trials

Journal Articles

Abstract A20: Development and validation of a novel acute myeloid leukemia xenograft model that is dependent on the JAK2^V617F mutation for growth in vivo

Leslie Lee, Emily Hanan, Aihe Zhou, Thomas Rawson, Ji Li, Pawan Bir Kholi, Kathy Barrett, Christine Chang, Jacob Chen, Savita Ubhayakar, Mike Siu, Jane Kenny, Wade Blair, Nico Ghilardi, Deepak Sampath

Mol Cancer Ther (2009) 8 (12_Supplement): A20.

https://doi.org/10.1158/1535-7163.TARG-09-A20

Published: 10 December 2009

View article titled, Abstract A20: Development and validation of a novel acute myeloid leukemia xenograft model that is dependent on the JAK2V617F mutation for growth in vivo

Journal Articles

MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo

Deepak Sampath, Carolyn M. Discafani, Frank Loganzo, Carl Beyer, Hao Liu, Xingzhi Tan, Sylvia Musto, Tami Annable, Patricia Gallagher, Carol Rios, Lee M. Greenberger

Mol Cancer Ther (2003) 2 (9): 873–884.

Published: 10 October 2003

View article titled, MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo

NARROW

Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

Neutralization of BCL-2/X_L Enhances the Cytotoxicity of T-DM1 In Vivo

Combined MEK and BCL-2/X_L Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness

An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody–Drug Conjugate for the Treatment of Hormone Receptor–Positive Breast Cancer

Abstract B052: FLT3-ITD activation mediates resistance to the BCL-2 selective antagonist, venetoclax, in FLT3-ITD mutant AML models

Expression Profile of BCL-2, BCL-X_L, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Abstract B190: GDC-0068 is a novel and selective Akt inhibitor that enhances the efficacy of FOLFOX in primary gastric cancer models.

Abstract B154: Co-administration of nicotinic acid with NAMPT small molecule inhibitors results in loss of in vivo efficacy in NAPRT1-deficient tumor models.

Abstract A245: Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101), and the novel Bcl-2 selective inhibitor, ABT-199 (GDC-0199), results in superior in vitro and in vivo anti-tumor activity in models of B-cell malignancies.

Abstract C150: Depletion of cellular NAD using the NAMPT inhibitor GNE-617 leads to oncosis blister cell death.

Bcl-2/Bcl-x_L Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

The Bcl-2/Bcl-X_L/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Abstract C201: A novel potent and selective inhibitor of PI3K/mTOR, GDC‐0980, currently in phase I clinical trials

Abstract A20: Development and validation of a novel acute myeloid leukemia xenograft model that is dependent on the JAK2^V617F mutation for growth in vivo

MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only